Javier Cortés, MD, PhD

Javier Cortés, MD, PhD, discusses the design of the ASPEN-09-03 trial and the development of CD47 as a biomarker in pretreated HER2-positive breast cancer.

Javier Cortés, MD, PhD, discusses additional TROPION-Breast02 end points supporting the first-line use of Dato-DXd in metastatic TNBC.

Javier Cortés, MD, PhD, discusses the rationale for analyzing outcomes with trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who have brain metastases.

Javier Cortés, MD, PhD, discusses primary outcomes and safety findings from a pooled analysis of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who have brain metastases.

Javier Cortés, MD, PhD, discusses the incidence and management of male patients with breast cancer in Spain.

Javier Cortes, MD, PhD, discusses updated progression-free survival data from the phase 3 KEYNOTE-355 study with pembrolizumab plus chemotherapy in previously untreated patients with locally recurrent, inoperable or metastatic triple-negative breast cancer.